Krystal Biotech Inc (NASDAQ:KRYS) CEO Krish S. Krishnan sold 27,879 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $50.41, for a total transaction of $1,405,380.39. Following the completion of the transaction, the chief executive officer now owns 2,024,567 shares in the company, valued at approximately $102,058,422.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
NASDAQ:KRYS traded up $1.06 during trading hours on Tuesday, hitting $54.07. The stock had a trading volume of 4,494 shares, compared to its average volume of 148,024. The company has a current ratio of 54.87, a quick ratio of 54.87 and a debt-to-equity ratio of 0.01. Krystal Biotech Inc has a 1-year low of $16.82 and a 1-year high of $54.67. The business has a 50 day simple moving average of $40.32 and a two-hundred day simple moving average of $40.01. The company has a market cap of $892.42 million, a PE ratio of -55.66 and a beta of 1.03.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.14. Research analysts expect that Krystal Biotech Inc will post -1.25 EPS for the current fiscal year.
Several research firms recently commented on KRYS. Goldman Sachs Group began coverage on shares of Krystal Biotech in a report on Tuesday, September 24th. They issued a “neutral” rating and a $60.00 price target on the stock. HC Wainwright set a $59.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a report on Wednesday, September 4th. William Blair restated a “buy” rating on shares of Krystal Biotech in a report on Monday, November 4th. Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Tuesday, November 5th. Finally, BidaskClub raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Krystal Biotech currently has an average rating of “Buy” and an average price target of $59.33.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: Depreciation
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.